MRRS adds "Global Cardiovascular Disease Market to 2022 – Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

Table of Contents
3 Key Marketed Products 29
3.1 Overview 29
3.2 Crestor (rosuvastatin) - AstraZeneca 29
3.3 Zetia (ezetimibe) - Merck & Co 30
3.4 Lipitor (atorvastatin) - Pfizer 32
3.5 Praluent (alirocumab) - Sanofi 34
3.6 Xarelto (rivaroxaban) - Bayer 35
3.7 Eliquis (apixaban) - Bristol-Myers Squibb and Pfizer 37
3.8 Plavix (clopidogrel) - Sanofi 38
3.9 Brilinta (ticagrelor) - AstraZeneca 40
3.10 Entresto (valsartan plus sacubitril) - Novartis 41
3.11 Benicar (olmesartan medoxomil) - Daiichi Sankyo 43
3.12 Conclusion 44
4 Pipeline Landscape Assessment 46
4.1 Overview 46
4.2 Pipeline Development Landscape 46
4.3 Molecular Targets in the Pipeline 49
4.4 Clinical Trials 53
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 53
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 57
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 60
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 63
4.5 Conclusion 66
5 Multi-Scenario Market Forecast to 2022 67......

List of Tables and Figures 
Table 1: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category 17
Table 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, 2016 20
Table 3: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Crestor, 2016 29
Table 4: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Zetia, 2016 31
Table 5: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Lipitor, 2016 33
Table 6: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Praluent, 2016 34
Table 7: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Xarelto, 2016 36
Table 8: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Eliquis, 2016 37
Table 9: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Plavix, 2016 39
Table 10: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Brilinta, 2016 40
Table 11: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Entresto, 2016 41
Table 12: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Benicar, 2016 43
Table 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022 68
Table 14: Cardiovascular Disease Therapeutics Market, Global, Usage of Generics Across Key Indications, 2015 70
Table 15: Cardiovascular Disease Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022 76.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-cardiovascular-disease-market-to-2022-sanofi-and-novartis-to-become-market-leaders-as-praluent-and-entresto-drive-revenue-growth

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/